Onychomycosis treatment compositions and methods
Liquid pharmaceutical compositions with high antifungal concentrations, using hydrophobic solvents and polymeric film-formers, address the challenges of onychomycosis by ensuring effective nail bed penetration and prolonged antifungal activity, eliminating the need for surgical intervention and systemic toxicity.
Patent Information
- Application Number
- JP2024114840
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-10-08
- Filing Date
- 2024-07-18
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for onychomycosis, such as oral and topical antifungal agents, face challenges in achieving therapeutically effective concentrations due to systemic toxicity, low penetration, and difficulty in maintaining antifungal agent concentrations for the duration required for nail growth, often necessitating surgical intervention.
Development of liquid pharmaceutical compositions with high concentrations of antifungal agents, utilizing a hydrophobic solvent and polymeric film-forming agents, administered subungually through a cannula to maximize adhesion, penetration, and retention in the nail bed and plate, avoiding systemic absorption.
The compositions achieve high topical dosages and prolonged antifungal activity, effectively eradicating fungal infections and dormant spores without systemic side effects, promoting nail regrowth with minimal trauma.
Smart Images

Figure 2024167183000001_ABST
Abstract
Description
Related Applications
[0001] This application claims priority to pending U.S. Provisional Patent Application No. 62 / 912,494, filed October 8, 2019, the contents of which are incorporated by reference. [Technical field]
[0002] The present disclosure relates to compositions and methods for treating the subungual space, and in particular to the treatment of onychomycosis and dermatophytoma. [Background technology]
[0003] The Background Description includes information that may be useful in understanding the present disclosure. The Background Description is not an admission that any information provided in this disclosure is prior art or relevant to the invention(s) claimed in this application, nor is it an admission that any publication specifically or implicitly referenced is prior art.
[0004] All publications and patent applications within this disclosure are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. If the definition or usage of a term in the incorporated reference is inconsistent with or conflicts with the definition of that term provided in this disclosure, the definition of that term provided in the disclosure shall apply and the definition of that term in the reference shall not apply.
[0005] Onychomycosis is a fairly common infection of the nail bed. Due to its location, it is difficult to deliver sufficiently high (therapeutically effective) concentrations of antifungal agents. Furthermore, because fungal infection involves cell and spore division, therapeutically effective concentrations are relatively high, even when relatively potent agents are used. For example, terbinafine is a potent antifungal agent that has been approved in oral form for the treatment of onychomycosis. Although oral forms are somewhat effective in treating the disease because they deliver the drug systemically to the soft tissues under the nail (nail bed) where the disease-causing dermatophyte grows, the systemic toxicity of terbinafine (especially hepatotoxicity) often limits the success of treatment. Indeed, it has been shown that monotherapy was associated with a high failure rate due to low local drug concentrations in the nail plate and the need for high minimum inhibitory concentrations (MICs) (see, e.g., Mycoses 2003, 46, 506-510). To improve efficacy, terbinafine administration may be accompanied by surgery to increase cure rates (Journal of Dermatological Treatment (2000) 11, 259-262). However, the treatment requires removal of the nail plate, which is less than desirable. Intermittent pulse dosing at 250 mg / day for 7 days every 2-4 months to reduce toxicity has at least somewhat improved results (see, for example, Arch Dermatol Vol 140, June 2004, p691-695). However, cure rates are still lower than desired, and potential toxicity remains an issue.
[0006] To avoid problems associated with high systemic exposure, antifungal agents may be applied topically to the nail plate. For example, an alcoholic solution of 10% efinaconazole (marketed as JUBLIA®) has been developed. Unfortunately, due to rather poor penetration into the nail plate, the rate of complete cure is rather low, ranging from 15.2% to 17.8% of the treated population (see FDA prescribing information).
[0007] Subungual administration has recently been proposed as a means of delivering antifungal agents to the site of infection, with example compositions and methods described in US Patent Publication No. 2013 / 0210925. For example, US Patent Publication No. 2010 / 0048724 and US Patent Publication No. 9,446,009 teach non-liquid terbinafine hydrochloride compositions for direct administration to the subungual space, and US Patent Publication No. 7,135,194 teaches solid or semi-solid formulations for subungual administration. In yet another example, semi-solids can be used for subungual delivery, as described in US Patent Publication No. 2004 / 0062733 and US Patent Publication No. 2007 / 0014743. However, while relatively high drug concentrations can be administered locally, delivery of terbinafine from solid or semi-solid carriers often does not facilitate diffusion of the active ingredient to adjacent areas. Moreover, such solid or semi-solid carriers often do not facilitate diffusion of the active ingredient into the nail bed and nail plate, and therefore the carrier must typically be inserted into the leading edge of the affected area, often resulting in trauma, puncture bleeding, and lifting of the nail plate.
[0008] In yet another attempt to reach the site of infection, a fluorescently labeled alcohol solution similar to an alcohol solution of efinaconazole was applied to the hyponychium and toe tip, spreading the solution under the nail surface and distal skin area. Notably, some of the applied solution appeared to penetrate through the hyponychium to the area between the nail bed and the nail plate, while other parts of the solution were attached to the nail plate (see J Drugs Dermatol 2014,Vol.13,No.11,1394-8). However, no antifungal agent was used, and therefore antifungal activity was not evaluated. Given the relatively low concentration of efinaconazole and the relatively small diffusion volume of the excipients, the efficacy of antifungal treatment with such a low concentration formulation is at best unreliable.
[0009] Further compounding the difficulties of known subungual applications is the presence of a polysaccharide matrix produced by the fungal mass, which manifests as a "dermatophytoma." Indeed, in areas with extensive polysaccharide matrix, the penetration of antifungal agents is reduced, rendering the condition resistant to standard antifungal treatment, and oral terbinafine in combination with surgical removal of the nail plate is often the only reasonably effective treatment.
[0010] Furthermore, it is difficult to maintain an effective antifungal concentration for the period required for the nail to grow healthy and healthy looking and to reach full healing. Nails grow 1 mm per month, and it takes 12 months for the nail to fully grow out. As a result, a longer-lasting antifungal reservoir capable of achieving a high local dose would be more effective. Unfortunately, the concentrations of currently known antifungal agents typically cannot achieve such high local doses. Furthermore, it should be understood that a 1000-fold higher concentration of antifungal agent is required to eradicate dormant fungal spores (see, e.g., Mycoses (2002) 46, 506-510).
[0011] Thus, while various compositions and methods are known in the art, all or nearly all of them suffer from various drawbacks. Accordingly, there is a need to provide improved compositions and methods that provide effective treatment of the subungual space, particularly those related to the treatment of onychomycosis and dermatophytosis. Summary of the Invention
[0012] Compositions and methods are presented for the treatment of onychomycosis and / or dermatophytosis using pharmaceutical compositions with controlled physicochemical parameters that maximize the subungual treatment area, local concentration, and retention of the therapeutic agent (which is most often an antifungal agent). Advantageously, the contemplated compositions also exhibit (1) high adhesion and penetration into the polysaccharide matrix often associated with dermatophytosis, (2) high local dose and effective drug availability, and (3) high secondary diffusion in the nail plate and nail bed with low systemic absorption of the therapeutic agent. Furthermore, the compositions can be administered clinically using methods that do not induce pain and / or trauma, and at doses that do not pose concerns about toxic side effects.
[0013] In one embodiment, the inventors contemplate a liquid pharmaceutical composition comprising a pharma- ceutically acceptable carrier (vehicle) containing a hydrophobic solvent, an optional polymeric film-forming agent, and an antifungal agent. Most typically, the antifungal agent is dissolved in the pharma- ceutically acceptable carrier and is present at a concentration of 10% by weight or more (more preferably 20% or more, and even more preferably 40% or more). The polymeric film-forming agent may be included in the composition to impart a viscosity of preferably about 500-2,500 cP (mPa·s), more preferably about 750-1,500 cP (mPa·s).
[0014] For example, in some embodiments, the hydrophobic solvent is benzyl alcohol, benzyl benzoate, isostearic acid, diisopropyl adipate, diethyl sebacate, and / or isopropyl myristate, suitable hydrophilic solvents include propylene carbonate, dimethyl isosorbide, and / or lactic acid, and suitable film formers include ethyl lactate, triethyl citrate, dimethyl, diethyl, or dibutyl phthalate, and / or substituted polymeric cellulose. With regard to suitable antifungal agents, it is contemplated that the antifungal agent may be an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent. Among the preferred antifungal agents are allylamine antifungal agents, particularly terbinafine.
[0015] In other examples, the antifungal agent may be present at a concentration of 20% by weight or more or 40% by weight or more and is stable for at least 4 weeks (or at least 12 weeks, or at least 6 months) when the composition is stored at 25° C. and 60% relative humidity. Thus, in some embodiments, the hydrophobic solvent may include isostearic acid, isopropyl myristate, and / or diisopropyl adipate, and may further include dimethyl isosorbide, propylene carbonate, lactic acid, or benzyl alcohol. Additionally, preferred polymeric film-forming agents include triethyl citrate and ethyl cellulose, among others. When the antifungal agent is terbinafine, it is further contemplated that the antifungal agent is terbinafine in the free base form.
[0016] Therefore, and from a different perspective, the present inventors also contemplate a high-dose antifungal liquid pharmaceutical composition comprising a hydrophobic solvent, a polymeric film-forming agent, and a pharma- ceutical acceptable carrier comprising an antifungal agent at a concentration of 30% or more by weight of the composition. Most typically, the antifungal agent is dissolved in the pharma- ceutical acceptable carrier, and the composition is stable for at least 4 weeks (or at least 12 weeks, or at least 6 months) when stored at 25° C. and a relative humidity of 60%, and the viscosity of the pharmaceutical composition is about 500 to 2,500 cP (mPa·s), more preferably about 750 to 1,500 cP (mPa·s).
[0017] In further contemplated embodiments, the antifungal agent is present in a concentration of 40% or more by weight of the composition, and preferred hydrophobic solvents include benzyl alcohol, isostearic acid, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and preferred hydrophilic solvents, when used, include dimethyl isosorbide, propylene carbonate, and lactic acid. More preferably, the polymeric film-forming agent comprises a substituted cellulose. Most typically, the antifungal agent is an allylamine antifungal agent, and a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent, and most preferably, the free base form of terbinafine.
[0018] In yet another aspect of the subject matter, the inventors contemplate a method of providing treatment to the subungual space of a mammal, comprising administering a liquid pharmaceutical composition to the subungual space between the nail plate and the nail bed. Most typically, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier, including a hydrophobic solvent in which the therapeutic agent is dissolved, and an optional film-forming agent, and the viscosity of the pharmaceutical composition is about 500-2,500 cP (mPa·s). It should further be noted that in the above method, the therapeutic agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the therapeutic agent in the subungual space, and preferably also in the treatment space. Most typically, the therapeutic agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the therapeutic agent in the subungual space and in treatment spaces extending beyond the subungual space. The use of a high concentration liquid formulation is particularly desirable, since access to the treatment space with solid implants has been associated with bleeding and trauma. In contrast, highly concentrated liquid formulations can be distributed throughout the subungual space, allowing diffusion of the active ingredient into the treatment space at the MIC.
[0019] Without limiting the subject matter of the invention, it is usually preferred that the step of administering the liquid pharmaceutical composition subungually comprises the step of atraumatically inserting a cannula between the nail plate and the nail bed, and another step of administering the liquid pharmaceutical composition through the cannula. Preferably, but not necessarily, said cannula is a blunt cannula with at least one side hole at the distal part of the cannula. It is further noted that the subungual space typically includes an area infected with a fungus where the nail plate has partially detached from the nail bed (onycholysis), and where the therapeutic agent is an antifungal agent. However, it is not essential that the liquid pharmaceutical composition is delivered directly to the infected area, and the liquid pharmaceutical composition may passively move to the infected area by migration and diffusion actions. Advantageously, the step of administering the liquid pharmaceutical composition further ensures a minimum therapeutic concentration of the therapeutic agent in the nail bed and the nail plate. It should be appreciated that in further advantageous embodiments, the compositions contemplated herein have concentrations of antifungal agents far in excess of the MIC, and therefore provide longer term antifungal protection, and in some cases may even be toxic to dormant spores.
[0020] In some embodiments, the hydrophobic solvent reduces the absorption rate of the therapeutic agent into the systemic circulation and increases the availability of the therapeutic agent to the nail bed and its surface, as compared to dimethylsulfoxide (DMSO) or dimethylformamide (DMF). Most typically, 10-100 μL of the liquid pharmaceutical composition is injected into the subungual space. It should be appreciated that in most embodiments, a gentle, non-traumatic mechanical piercing action with a blunt cannula penetrates the porous polysaccharide matrix produced by the dermatophyte, and that the liquid state allows for lateral flow through the porous matrix and polymeric film-forming agent, and / or the viscosity of the liquid pharmaceutical composition typically allows for lateral flow within the subungual space without excessive expression or loss from the subungual space. It is therefore notable that the viscosity of exemplary liquid pharmaceutical compositions allows for retention of 80% or more of the administered volume of the liquid pharmaceutical composition in the subungual space.
[0021] Most preferably, the hydrophobic solvent is isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and / or isopropyl myristate, the preferred hydrophilic solvent is dimethyl isosorbide, propylene carbonate, and / or lactic acid, the polymeric film-forming agent is a substituted cellulose (e.g., ethyl cellulose), and / or the therapeutic agent is an antifungal agent such as an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, and / or an azole antifungal agent.
[0022] In yet another aspect of the inventive subject matter, the inventors also contemplate a method of treating onychomycosis comprising administering subungually a liquid pharmaceutical composition containing a hydrophobic solvent, an optional hydrophilic solvent, an optional polymeric film-forming agent, and a pharma- ceutically acceptable carrier comprising an antifungal agent. The antifungal agent is preferably present in a concentration of 10% by weight or more dissolved in the pharma- ceutically acceptable carrier, and the pharmaceutical composition has a viscosity of about 500-2,500 cP (mPa·s). Most typically, the antifungal agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the antifungal agent in the subungual space and in the treatment space extending beyond the subungual space.
[0023] As mentioned above, it is contemplated that the hydrophobic solvent may be isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and / or isopropyl myristate, the suitable hydrophilic solvent may be dimethyl isosorbide, propylene carbonate, and / or lactic acid, the polymeric film former is a substituted cellulose, and / or the antifungal agent is an antifungal agent such as an allylamine antifungal agent (most preferably terbinafine), a morpholine antifungal agent, a polyene antifungal agent, and / or an azole antifungal agent.
[0024] In some embodiments, the antifungal agent is present in a concentration of 20% by weight or more and is stable for at least 4 weeks when the composition is stored at 25° C. and 60% relative humidity, or the antifungal agent is present in a concentration of 40% by weight or more and is stable for at least 4 weeks when the composition is stored at 25° C. and 60% relative humidity. Furthermore, when the composition is stored at 5° C., the composition remains stable in a homogeneous, flowable form for at least 4 weeks. In other embodiments, the composition has a concentration of about 750 to 1,500 cP (mPa·s). For example, the hydrophobic solvent may contain isopropyl myristate and / or diisopropyl adipate, and optionally benzyl alcohol, and the antifungal agent is terbinafine free base.
[0025] Accordingly, the inventors also contemplate a method of treating dermatophytosis comprising administering subungually a liquid pharmaceutical composition into a polysaccharide matrix between the nail plate and the nail bed, wherein the liquid pharmaceutical composition comprises a hydrophobic solvent, an optional hydrophilic solvent, a polymeric film-forming agent, and an antifungal agent, the antifungal agent being dissolved in a pharma- ceutically acceptable carrier and present in a concentration of 20% by weight or greater, and wherein the viscosity of the pharmaceutical composition is about 500-2,500 cP (mPa·s).
[0026] Most typically, the hydrophobic solvent may be benzyl alcohol, isostearic acid, diisopropyl adipate, diethyl sebacate, and / or isopropyl myristate, the hydrophilic solvent may optionally include dimethyl isosorbide, propylene carbonate, and / or lactic acid, the polymeric film-forming agent may include substituted cellulose, and / or the antifungal agent may be an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent. In the above method, when the composition is stored at 25° C. and a relative humidity of 60%, the antifungal agent may be present at a concentration of 40% by weight or more and stable for at least 4 weeks, and / or the concentration of the composition may be about 750 to 1,500 cP (mPa·s). For example, a preferred hydrophobic solvent may contain isostearic acid, isopropyl myristate, and / or diisopropyl adipate, and an optional benzyl alcohol, and the antifungal agent is terbinafine free base.
[0027] In yet another aspect of the subject matter of the invention, we contemplate a method of treating onychomycosis comprising administering a liquid pharmaceutical composition subungually through a cannula inserted at a location that does not require contact with the visible proximal end of the onychomycosis, the liquid composition migrating to the visible proximal end of the onychomycosis. Most typically, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier that includes a hydrophobic (and optionally hydrophilic) solvent, a polymeric film-forming agent, and an antifungal agent dissolved in a hydrophobic / hydrophilic solvent mixture, the viscosity of the pharmaceutical composition being about 500-2,500 cP (mPa·s). When administered subungually, the liquid pharmaceutical composition is then allowed to migrate from said location to at least the visible proximal end of the onychomycosis. Most typically, the antifungal agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the antifungal agent in the subungual space and in the treatment space extending beyond the subungual space.
[0028] For example, the location (of the cannula) is at least 1 mm or at least 3 mm away from the visible proximal end of the onychomycosis lesion.Furthermore, subungual administration is usually preferred using a step of delivering the liquid pharmaceutical composition through a blunt cannula.
[0029] From yet another perspective, the present inventors also contemplate a method for retaining a liquid pharmaceutical composition containing an antifungal agent in the subungual space, comprising the step of subungually administering the liquid pharmaceutical composition to the subungual space. Most typically, the liquid pharmaceutical composition contains a pharma- ceutical acceptable carrier including at least a hydrophobic solvent and a polymeric film-forming agent, and the antifungal agent is dissolved in the pharma- ceutical acceptable carrier. Most typically, the viscosity of the liquid pharmaceutical composition is about 750 to 1,500 cP (mPa·s), or about 500 to 2,500 cP (mPa·s).
[0030] Preferably, but not necessarily, 80% or more, or 90% or more of the administered volume is retained in the subungual space. As mentioned above, preferred hydrophobic solvents include benzyl alcohol, isostearic acid, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, while hydrophilic solvents are optional and may be dimethyl isosorbide, propylene carbonate, and / or lactic acid, and preferred polymeric film formers include substituted celluloses (e.g., ethyl cellulose). In most embodiments, the antifungal agent is an allylamine antifungal agent (e.g., terbinafine), a morpholine antifungal agent, a polyene antifungal agent, and / or an azole antifungal agent. Advantageously, when the composition is stored at 25° C. and 60% relative humidity, the antifungal agent is present at 20% by weight or more, or 30% by weight or more, or 40% by weight or more, and is stable for at least 4 weeks. In an even more preferred aspect, the antifungal agent is stable under refrigeration at or below room temperature (eg, 4-5° C.).
[0031] Various objects, features, aspects and advantages will become more apparent from the following more detailed description of preferred embodiments, taken in conjunction with the accompanying drawings. [Brief description of the drawings]
[0032] [Figure 1] 1 is a photograph of an example of a toenail affected by onychomycosis.
[0033] [Diagram 2] 1 is a graph depicting terbinafine concentrations by different modes of administration.
[0034] [Diagram 3] 1 is a graph depicting terbinafine plasma concentrations versus time following single-agent topical administration of approximately 4.2 mg / kg terbinafine applied directly to the skin to Hanford minipigs.
[0035] [Figure 4]1 is a graph depicting terbinafine plasma concentration versus time following single-agent local administration of approximately 4.2 mg / kg terbinafine to Hanford minipigs applied to the Hilltop chamber.
[0036] [Diagram 5] FIG. 1 is a graph depicting terbinafine plasma concentrations versus time following single-agent topical administration of approximately 42 mg / kg terbinafine applied directly to the skin (10 application sites) to Hanford minipigs.
[0037] [Figure 6] FIG. 1 is a graph depicting terbinafine plasma concentration versus time following single topical administration of approximately 42 mg / kg terbinafine to Hanford minipigs applied to the Hilltop Chamber (10 application sites).
[0038] [Figure 7] 1 is a graph depicting terbinafine plasma concentrations versus time following single-agent topical administration of about 4.2 mg / kg or about 42 mg / kg terbinafine applied directly to the skin to Hanford minipigs.
[0039] [Figure 8] 1 is a graph depicting terbinafine plasma concentration versus time following single-agent local administration of about 4.2 mg / kg or about 42 mg / kg terbinafine to Hanford minipigs applied to the Hilltop chamber. Detailed Description of the Invention
[0040] The inventors have discovered a liquid pharmaceutical composition for subungual administration that allows high concentrations of antifungal agents to be achieved in a pharma- ceutically acceptable carrier. Contemplated carriers include a hydrophobic solvent, an optional hydrophilic solvent, and an optional polymeric film-forming agent, and the pharmaceutical composition has a viscosity that allows not only targeted delivery to the subungual space through a small-bore cannula, but also passive distribution of the liquid pharmaceutical composition laterally, proximally, and distally through the subungual space, typically via migration, capillary action, and / or surface tension. Advantageously, the compositions presented in the present disclosure also allow the antifungal agent to diffuse to the nail plate at concentrations above the MIC, while avoiding systemic absorption into the patient's circulatory system. Furthermore, the compositions presented in the present disclosure allow the pharmaceutical composition to be distributed into and through the polysaccharide matrix of dermatophytosis, and are therefore suitable for the treatment of onychomycosis and dermatophytosis. In this context, it should be noted that while the pharmaceutical composition is effective as a monotherapy (i.e., does not include a second agent), the composition can include additional therapeutic agents.
[0041] As used in this disclosure, it is important to recognize that the term "subungual space" refers to a pre-existing space that exists between the nail bed and the nail plate and is the result of fungal growth in humans with onychomycosis. From a different perspective, the subungual space may be considered as a contiguous open space that may be empty or may contain debris from keratin, collagen, and / or fungal material (e.g., polysaccharide matrix). Thus, the subungual space is a variable space that may typically span a significant portion of the nail organ and may further include areas of coexisting current and / or past fungal growth. Thus, from the perspective of drug administration, the subungual space is a space that is accessible from a location outside the nail organ without damage or separation to the nail plate and nail bed when accessed. For example, administration of the compositions contemplated in this disclosure may be performed with a small gauge blunt cannula without causing pinpoint bleeding or separation between the nail plate / nail bed.
[0042] Thus, the term "subungual space" is distinct from the term "treatment space" in that the treatment space is also outside the subungual space, but includes an area where the active ingredient is present (e.g., through diffusion) in an amount that is preferably at least the MIC (minimum inhibitory concentration) of the active ingredient. Thus, in most cases, the treatment space is larger than the subungual space and includes an area that is not in direct contact with the treatment composition. For example, the treatment space typically includes a space where the active ingredient is present due to diffusion or nail growth. For example, when a highly concentrated terbinafine solution is administered non-traumatically to the subungual space, the treatment space includes the space adjacent to the subungual space where terbinafine is present at least at the MIC, and the part of the nail plate where terbinafine has diffused. In particular, as the nail grows distally, the area of the nail plate may continually expand the treatment space.
[0043] With respect to the term "liquid" as used in conjunction with compositions contemplated in this disclosure, it is noted that the term liquid refers to a composition that contains a liquid component (typically a solvent that is liquid at room temperature) having one or more other components (e.g., antifungal agents) dissolved, dispersed, or distributed therein. Additionally, solids may be destabilized in an amorphous phase and may then appear to be liquids. Thus, the terms "liquid" composition and "flowable" composition are used interchangeably in this disclosure. Most typically, liquids contemplated in this disclosure have a dynamic viscosity of 500-2,500 cP.
[0044] It should therefore be appreciated that the contemplated compositions and methods provide therapeutic coverage of the entire fungal nail bed, thereby eradicating vegetative and non-vegetative spores so that the fungal tissue is replaced (simultaneous with linear growth) by a new, disease-free nail plate and the nail bed underneath. The relatively high concentration of the active ingredient (preferably terbinafine) creates a reservoir that can spread proximally from the deposition site through the ridges and sinuses of the nail bed. Furthermore, due to the hydrophobic nature of the carrier, the active ingredient is rapidly absorbed into the nail plate, forming an antifungal barrier that can prevent fungal penetration proximally and anteriorly. It should also be appreciated that the hydrophobic nature of the carrier reduces systemic absorption of the active ingredient while promoting distribution of the active ingredient into the nail plate. Moreover, the contemplated formulations have a viscosity that is compatible with the distribution of fluids in the subungual space and the ability to inject the formulation through a small-bore cannula (e.g., a blunt-tip 30-gauge cannula), thereby preventing or significantly reducing further lifting of the nail plate (onycholysis). Such a cannula is also blunt enough to allow the active ingredient to reach the center of the fungal nail bed space without trauma or damage to the nail bed epithelium, and precise enough to allow the practitioner to treat difficult-to-treat fungal mass (dermatophytosis) entry points, such as the lateral margins. From a different perspective, the suitable viscosity of the contemplated formulations balances many of the conditions necessary for therapeutic efficacy. It allows the liquid composition to be retained in the subungual space in therapeutic amounts, while allowing the liquid formulation to be administered and passively distributed throughout the subungual space (e.g., via capillary action and / or mechanical forces due to toe movements) without loss due to leakage. Most preferably, such administration is accomplished using a blunt cannula sized to prevent trauma.
[0045] It should therefore be understood that the contemplated terbinafine (or other antifungal) liquid formulation for the treatment of onychomycosis aims at a flowable liquid form of terbinafine that can be delivered locally on the surface of the nail bed (and / or further if necessary) at very high local drug concentrations. The concentrated viscous liquid formulation is preferably delivered through a small bore cannula and is moved to the hard-to-reach border of the diseased area by substantially filling the subungual space created by the disease. In this context, it should be noted that the movement of the drug is mainly due to the action of the liquid flow and is less dependent on the diffusion of the drug into the tissue. Drug delivery also benefits from the pumping action that results from the periodic pressure pulses that are generated within the nail unit as the patient walks and applies pressure to the toes. The small bore cannula is also an effective tool to penetrate the debris created by dermatophytes in the subungual space. Dermatophytosis, a form of fungal disease that causes unsightly yellow spikes on the nails, is caused by a polysaccharide matrix formed by the fungus and is known to be difficult to treat due to poor drug penetration. In particular, the insertion of a cannula through the diseased matrix and placement of liquid medication in a central location in the diseased area has been shown to be an effective delivery method.
[0046] In particular, it should be appreciated that local delivery and retention of the active antifungal agent (preferably terbinafine) at the affected area is not dependent on systemic absorption of the drug. In fact, the use of a hydrophobic solvent prevents the active antifungal agent (preferably terbinafine) from distributing into the capillary system of the nail bed. Thus, very high local drug concentrations are achieved by the local subungual administration method without the risk of hepatotoxicity associated with oral drug administration.
[0047] Terbinafine is most commonly provided as the hydrochloride salt, which is a crystalline, high melting solid. A free base form of terbinafine is also known, which is a crystalline solid with a lower melting point. The liquid state of terbinafine can be prepared by dissolving the solid in a solvent. However, the achievable concentration is limited by the solubility and pharmaceutical acceptability of the solvent used. More useful for achieving high drug concentrations is amorphous terbinafine, which is liquid at room temperature. Thus, amorphous terbinafine may be prepared by identifying a suitable crystallization inhibitor designed to prevent the formation of a thermodynamically favorable crystalline solid. However, the low melting free base form is more suitable for stabilizing the material in the liquid state, and furthermore has the advantage of not having the material weight associated with the counterion of the salt form.
[0048] For example, one particularly contemplated liquid pharmaceutical composition contains a pharma- ceutically acceptable carrier that includes a hydrophobic solvent, an optional hydrophilic solvent, a polymeric film-forming agent, and an antifungal agent, the antifungal agent being stabilized or dissolved in the pharma- ceutically acceptable carrier and present at a concentration of 10% by weight or more, or 20% by weight or more, or 40% by weight or more, and the viscosity of the pharmaceutical composition is about 500-2,500 cP (mPa·s). In a preferred embodiment, the hydrophobic solvent contains diisopropyl adipate, isopropyl myristate, isostearic acid, and benzyl alcohol as cosolvents, ethylcellulose as the polymeric film-forming agent, and 40% by weight or more of terbinafine as the antifungal agent. Thus, the viscosity of the pharmaceutical composition may be approximately 750-1,500 cP (mPa·s).
[0049] With regard to suitable hydrophobic solvents, it should be noted that various solvents, solvent systems, and crystallization inhibitors are also considered suitable, and particularly contemplated hydrophobic solvents and co-solvents include benzyl alcohol, isostearic acid, isostearyl alcohol, cinnamyl alcohol, benzyl benzoate, diisopropyl adipate, diethyl sebacate, and / or isopropyl myristate. Further contemplated hydrophobic solvents include various alkanes, alkanols, dialkyl ethers, cycloalkanes, various saturated and unsaturated fatty acids (oleic acid, linoleic acid, etc.), esters (oleyl oleate), monoglycerides (glycerol monooleate), diglycerides, triglycerides, natural and synthetic oils (sesame oil, soybean oil, peanut oil, corn oil, olive oil, vegetable oil, etc.), and the like. For example, alternative solvents and co-solvents include hexane, cyclohexane, benzene, toluene, diethyl ether, 1,4-dioxane, castor oil, and the like. In further contemplated embodiments, such hydrophilic solvents can be included in the carrier, especially when a hydrophilic solvent that is miscible with the hydrophobic solvent is used. Particularly contemplated hydrophilic solvents with dual miscibility in the hydrophobic and hydrophilic phases include 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide, propylene carbonate, and D,L-lactic acid. In further contemplated embodiments, terbinafine free base is dissolved in a solution of a solid or liquid acid dissolved in a solvent. Inorganic acids include phosphoric acid and hydrochloric acid, and organic acids include D- and / or L-lactic acid, malic acid, maleic acid, malonic acid, fumaric acid, tartaric acid, succinic acid, citric acid, acetic acid, ascorbic acid, and propionic acid. Solvents that dissolve acids include ethanol, isopropanol, acetone, benzyl alcohol, and acetophenone.
[0050] In this regard, it should be appreciated that preferred solvents, solvent systems, and crystallization inhibitors (e.g., those having two or more solvents, typically in a single-phase mixture, as a mixture of solvents or inhibitors) dissolve or prevent precipitation of the active ingredient (particularly terbinafine salt or terbinafine free base) at a concentration of 15% by weight or more, or 20% by weight or more, or 25% by weight or more, or 30% by weight or more, or 35% by weight or more, or 40% by weight or more, or 45% by weight or more. For example, suitable active ingredient (e.g., terbinafine) concentrations in hydrophobic solvents are 10-15% by weight, or 15-20% by weight, or 20-25% by weight, or 25-30% by weight, or 30-35% by weight, or 35-40% by weight, or 40-45% by weight, or 45-50% by weight, or even higher. Thus, the terbinafine concentration may be 15-30% by weight, or 25-40% by weight, in particular 40% by weight, or 41% by weight, or 42% by weight, or 43% by weight, or 44% by weight, or 45% by weight.
[0051] Moreover, it is preferred that the active ingredient so dissolved or liquefied remains stable (i.e., does not precipitate) in a flowable physical form for an extended period of time, e.g., at least 1 week, at least 2 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weeks, or at least 6 months, or at least 1 year, when the composition is stored at 25° C. and 60% relative humidity. Most preferably, the antifungal agent is stable at the concentrations used over extended periods of time (e.g., at least 1 week, at least 2 weeks, at least 4 weeks, at least 8 weeks, or at least 12 weeks, or at least 6 months, or at least 1 year), even when stored at low temperatures (e.g., 4-5° C.).
[0052] Regarding terbinafine, it is most commonly provided as the hydrochloride salt, which is also intended to be a crystalline high melting solid. A form of terbinafine free base is also known, which is a crystalline solid with a lower melting point. A liquid form of terbinafine can be prepared by dissolving the solid in a solvent. However, the achievable concentration is limited by the solubility and pharmaceutical acceptability of the solvent used. Amorphous terbinafine, which is liquid at room temperature, is more useful for achieving high drug concentrations. Amorphous terbinafine may be prepared by identifying a suitable crystallization inhibitor designed to prevent the formation of a thermodynamically favorable crystalline solid. A low melting free base form is more suitable for stabilizing the substance in the liquid state, and further has the advantage of not having the material weight associated with the counter ion in the salt form. From a different perspective, a terbinafine formulation can be prepared in which terbinafine is present in a supersaturated form without precipitation or crystallization.
[0053] Of course, it should be understood that while terbinafine is a particularly preferred antifungal agent, a variety of other antifungal or therapeutic agents are also contemplated as suitable for use in the present disclosure, with particularly contemplated alternative antifungal agents including various allylamine antifungals (e.g., naftifine, tolnaftate), morpholine antifungals (e.g., amorolfine), polyene antifungals (e.g., amphotericin B, nystatin, natamycin, rimocidin, candicin), and / or azole antifungals (e.g., clotrimazole, miconazole, ketoconazole, itraconazole, fluconazole). Most typically, the drug concentration of contemplated liquid pharmaceutical compositions will be 10% by weight or more, more typically 15% by weight or more, or 20% by weight or more, or 25% by weight or more, or 30% by weight or more, or 35% by weight or more, or 40% by weight or more, or even higher. For example, contemplated alternative antifungal concentrations in the hydrophobic solvent are 5-10%, 10-15%, or 15-20%, or 20-25%, or 25-30%, or 30-35%, or 35-40%, or 40-45%, or 45-50%, or even higher. Thus, the terbinafine concentration may be 15-30%, or 25-40%, and in particular 40%, or 41%, or 42%, or 43%, or 44%, or 45% by weight.
[0054] Advantageously, even at such high concentrations, systemic absorption is typically reduced or completely avoided due to the hydrophobic nature of the liquid pharmaceutical composition. Thus, systemic and / or hepatic side effects are substantially eliminated. Moreover, at such high concentrations, terbinafine and other alternative agents have a significant bactericidal effect, even effective against spore forms of nail fungus. In fact, it has been shown that the proposed formulation can be used to achieve concentrations many times the MIC required to kill spores in the nail plate and nail bed.
[0055] Suitable polymeric film-forming agents include especially linear polymeric film-forming agents, which may have a polymer or copolymer backbone. For example, suitable linear polymeric film-forming agents may be based on carbohydrate or polyethylene backbones with suitable substituents, or may be based on polyvinylpyrrolidone backbones. Similarly, suitable film-forming agents also include various acrylates, acrylamides, etc. Most preferably, the polymeric film-forming agent is soluble in hydrophobic solvents and is also a hydrophobic film-forming agent by itself. In addition, the film-forming agent can also interfere with the physical stability of the active ingredient (e.g., prevent the active ingredient from precipitating and crystallizing), thereby providing a uniform and flowable physical form at all intended storage temperatures, such as the temperature during refrigeration. Thus, contemplated film-forming agents include alkyl celluloses (especially ethyl cellulose), hydroxyalkyl celluloses (especially hydroxypropyl cellulose), various forms of carbomers (crosslinked acrylic acid) and glycols, etc. From a different perspective, preferred film-forming agents include, in particular, low polarity film-forming agents that dissolve in hydrophobic carriers at the concentration required to achieve the desired viscosity. Alternative film-forming agents may include triethyl citrate, triacetin, trimethyl citrate, triethyl citrate, tributyl citrate, diethyl phthalate, dibutyl phthalate, ethyl lactate, fatty acids (lauric acid, stearic acid, isostearic acid, capric acid, caprylic acid), fatty acid esters (glyceryl mono- or di-stearate, glyceryl monooleate), alkyl alcohols (stearyl alcohol, cetostearyl alcohol) and ethers (cetostearyl ether).
[0056] In a particularly preferred embodiment, the hydrophobic solvent and film-forming agent are formulated to provide a viscosity of the resulting liquid pharmaceutical composition that allows for subungual administration through a small bore cannula, typically at least 25 gauge, more preferably 27 gauge, and even more preferably 30 gauge (or less). Moreover, the viscosity is also sufficiently high to retain the administered volume within the subungual space, such that 50% or more, or 60% or more, or 70% or more, or 80% or more, or 90% or more, or 95% or more of the administered volume of the liquid pharmaceutical composition remains within the subungual space without being drained or expelled during normal daily activities. Moreover, the preferred film-forming agent facilitates distribution of the formulation substantially throughout the subungual space, typically by capillary action, wicking, and / or surface tension. In yet another contemplated embodiment, the film-forming agent also facilitates penetration of the formulation through the polysaccharide matrix between the nail bed and the nail plate of dermatophytosis. Advantageously, such penetration allows treatment of areas previously deemed untreatable.
[0057] Thus, in some embodiments, a film-forming agent is added to the formulation in an amount to provide a viscosity suitable for administration through a cannula and retention in the subungual space. For example, contemplated viscosities are 500-700 cP (mPa·s), or 700-900 cP (mPa·s), or 800-1,200 cP (mPa·s), or 1,000-1,500 cP (mPa·s), or 1,200-1,800 cP (mPa·s), or 1,500-2,000 cP (mPa·s), or 1,800-2,200 cP (mPa·s), or 2,000-5,500 cP (mPa·s), or 2,500-4,000 cP (mPa·s), or even higher in some cases. Thus, contemplated viscosities are typically less than 3,000 cP, less than 2,500 cP, less than 2,000 cP, less than 1,800 cP, less than 1,500 cP, or less than 1,000 cP. In other embodiments, contemplated viscosities are 500 cP or more, or 600 cP or more, or 700 cP or more, or 800 cP or more, or 900 cP or more, or 1,000 cP or more.
[0058] Thus, most notably, it should be recognized that the combination of a hydrophobic solvent and a polymeric film-forming agent retains the liquid pharmaceutical composition within the subungual space while facilitating lateral, proximal, and distal movement within the subungual space during or after administration into the subungual space. Furthermore, with certain compositions, the liquid pharmaceutical composition also penetrates into and through the polysaccharide matrix that is often associated with fungal infections. Thus, administration of the contemplated formulation does not necessarily have to be performed to the very tip of the affected area, but may be performed at a location somewhat away from the edge (e.g., at least 1 mm away, or at least 2 mm away, or at least 3 mm away, or at least 5 mm away).
[0059] Moreover, upon suitable selection of the solvent, the concentration of the active agent can be selected to be high enough to achieve the MIC not only in the subungual space, but also in the entire treatment area adjacent to and extending from the infected area in the subungual space. Indeed, due to the hydrophobic nature of the liquid pharmaceutical composition, the active ingredient (particularly terbinafine) can diffuse into the nail plate and nail bed and be present in the nail plate and / or nail bed at a therapeutically effective concentration (e.g., 1x or more of the MIC, or 2x or more of the MIC, or 5x or more of the MIC, or 10x or more of the MIC). Thus, it should be understood that the therapeutic effect (e.g., killing of fungi, and in many cases even killing of spores) can be achieved not only in the subungual space, but also in a treatment space that is significantly larger than that. Thus, it is contemplated that the treatment space is 105% or more, or 110% or more, or 115% or more, or 120% or more, or 125% or more, or at least 130% or even more of the subungual space. Furthermore, it should be appreciated that due to the very high concentrations of terbinafine in the contemplated formulations and use of hydrophobic solvents in such formulations (allowing terbinafine to be preferentially distributed to the nail plate rather than the systemic circulation), the MIC for exerting an antifungal effect in the subungual space and treatment space can be maintained for at least 1-3 days, or at least 3-7 days, or at least 14 days, or at least 30 days, or at least 60 days, or at least 90 days, or even longer.
[0060] Thus, and viewed from a different perspective, the terbinafine concentration under the nail and / or in the treatment space can be maintained at or above the MIC for at least 7 days, or at least 14 days, or at least 30 days, upon administration of a single liquid formulation having a volume of 100 μL or less, or a volume of 90 μL or less, or a volume of 80 μL or less, or a volume of 70 μL or less, or a volume of 50 μL or less, or a volume of 40 μL or less, or a volume of 30 μL or less, or a volume of 20 μL or less, or a volume of 10 μL or less.
[0061] In particular, the increased therapeutic efficacy is believed to result from a higher concentration of the antifungal agent (e.g., terbinafine), motility and retention of the antifungal agent (e.g., terbinafine) in the subungual space at higher concentrations, and diffusion of the antifungal agent (e.g., terbinafine) from the hydrophobic solvent into the nail plate to achieve a therapeutically effective concentration in the nail plate. As the nail plate progresses distally during nail growth, the antifungal agent (e.g., terbinafine) diffused and retained within the nail plate provides an effective barrier against fungal growth and re-establishment, ultimately resulting in replacement of the diseased nail plate with a healthy nail plate throughout growth.
[0062] As will be readily understood, contemplated pharma- ceutically acceptable carriers may include additives such as antioxidants and / or diluents, and non-functional agents such as pigments, dyes, and fluorescent agents to aid in visualization, if desired. If desired, stabilizers may be included to counteract precipitation or crystallization, but it should be understood that in some embodiments, the carriers are stable in a flowable physical form at very high concentrations for at least 4 weeks, or at least 8 weeks, or at least 12 weeks, or at least 6 months, or at least 9 months, or at least 12 months, when stored under standard conditions (25° C., 60% relative humidity). Additionally, additives such as ciclopirox olamine may be added to contemplated formulations if eradication of dormant spores is desired.
[0063] Thus, and viewed from a different perspective, embodiments of the present subject matter are also directed to a high-dose antifungal liquid pharmaceutical composition comprising a hydrophobic solvent, a polymeric film-forming agent, and a pharma- ceutically acceptable carrier comprising an antifungal agent in a concentration of 20% or more, or 25% or more, or 30% or more, or 35% or more, or 40% or more by weight of the composition. Most typically, when the composition is stored at 25°C and 60% relative humidity, the antifungal agent is maintained in a flowable physical form in the pharma- ceutical acceptable carrier and is stable for at least 4 weeks, and the composition has a concentration of about 500-2,500 cP (mPa·s). As mentioned above, it should also be understood that the stability of the formulation can be extended to more than 4 weeks, and typical stability periods are at least 8 weeks, at least 12 weeks, at least 6 months, at least 9 months, and at least 1 year, or even longer, when the composition is stored at 25°C and 60% relative humidity. The same considerations as above regarding hydrophobic solvents, hydrophilic solvents, polymeric film-forming agents, and antifungal agents apply.
[0064] Moreover, it should be noted that the formulations proposed in this disclosure are generally suitable as vehicles for subungual administration of any drug where it is desired that the formulation be retained in the subungual space for an extended period of time. Most typically, 50% or more, or 60% or more, or 70% or more, or 80% or more, or 90% or more, or 92% or more, or 95% or more of the formulation is retained for at least 1 day, or at least 3 days, or at least 1 week, or at least 2 weeks, or at least 3 weeks, or at least 4 weeks, or at least 2 months, or even longer.
[0065] In view of the above, it should therefore be appreciated that the contemplated uses include various methods of subungual administration, particularly to mammals. In such methods, the liquid pharmaceutical composition presented in the present disclosure is administered subungually to the space located between the nail plate and the nail bed, typically through the hyponychium or through direct administration from a cannula inserted into the subungual space beyond the hyponychium. In this context, it should also be appreciated that administration of the liquid pharmaceutical composition does not necessarily require an initial direct contact with the affected area or border of infection, since the liquid composition is flowable and can passively move to the affected area (e.g., by pressure and release during normal daily activities). Typically, administration through a cannula requires the insertion of the cannula through the hyponychium and the entry of the cannula into the subungual space between the nail plate and the nail bed. Most preferably, the cannula is a blunt cannula (e.g., 25 gauge, 28 gauge, 30 gauge) with one or two side holes at the distal portion of the cannula. It is further preferred that the liquid pharmaceutical composition is administered to fill 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more of the space between the nail bed and the nail plate. If desired, administration can also include topical administration to the lateral nail fold. Administration can also be performed in the open space between the nail bed and the nail plate where fungus is abundant.
[0066] Because the formulation is administered as a liquid that can enter areas of the subungual space that are difficult to access directly with a cannula, it can be administered non-traumatically into the subungual space (i.e., without causing bleeding and / or lifting of the nail plate or separation of the nail plate from the nail bed), resulting in significantly improved comfort and adherence to treatment and without the need for anesthetics.
[0067] Thus, the contemplated method is particularly suitable for treating onychomycosis, in which the liquid pharmaceutical composition is administered subungually. Most typically, the liquid pharmaceutical composition contains a pharma- ceutical carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, a polymeric film-forming agent, and an antifungal agent, the antifungal agent being maintained in a flowable physical form in the pharma- ceutical carrier and present in a concentration of 10% by weight or more (e.g., 20% by weight or more, or 30% by weight or more, or 40% by weight or more). As mentioned above, it is generally more preferred that the pharmaceutical composition has a viscosity of about 500 to 2,500 cP (mPa·s). Similarly, in view of enhanced penetration into and through the polysaccharide matrix, the inventors further contemplate a method of treating dermatophytoses (previously considered difficult or untreatable without removal of the nail) in which the liquid pharmaceutical composition is administered subungually to the polysaccharide matrix located between the nail bed and the nail plate without removal of the nail plate. Most typically, the antifungal agent is maintained in a fluid physical form in the pharma- ceutically acceptable carrier and is present in a concentration of 20% by weight or more, and the pharmaceutical composition has a viscosity of about 500-2,500 cP (mPa·s).With respect to suitable liquid pharmaceutical compositions, the same considerations as above apply.
[0068] From another perspective, the present inventors also contemplate a method of retaining a liquid pharmaceutical composition comprising an antifungal agent in the subungual space. In this context, it is important to understand that not only administration of the pharmaceutical composition but also effective penetration and retention at the affected area (and ideally at the nail plate) enhances the success rate of treatment. In such a method, a liquid pharmaceutical composition is administered subungually to the subungual space, as described above. Advantageously, due to the hydrophobic nature of the formulation, passive runoff (e.g., from showering or bathing) is also significantly reduced. When terbinafine free base is used, such advantages are further amplified.
[0069] Upon administration, it is typically contemplated that 60% or more, or 70% or more, or 80% or more, or 85% or more, or 90% or more of the administered amount is retained in the subungual space. Most typically, retention lasts for at least 6 hours, or at least 12 hours, or at least 24 hours, or at least 2 days, or at least 7 days. In this manner, very high concentrations of antifungal agent are administered locally and retained in the treatment space (advantageously maintaining antifungal agent concentrations much higher than the MIC, as discussed above). For example, absorption into local tissues (nail bed and nail plate) provides a significantly higher, therapeutic drug concentration for at least 1 month, or at least 2 months, or at least 3 months, and even longer.
[0070] Because of the ability of the contemplated formulations to migrate into the subungual space and diffuse to a larger treatment area, the inventors also contemplate a method of treating onychomycosis in which the liquid pharmaceutical composition presented in this disclosure is administered subungually to a location that does not contact the visible proximal edge of the onychomycosis area. The liquid pharmaceutical composition can then passively migrate from the location to at least the visible proximal edge of the onychomycosis area, typically via pressure / depressurization of the treatment area while walking. For example, the location is at least 1 mm, or at least 2 mm, or at least 3 mm, or at least 5 mm away from the visible proximal edge of the onychomycosis area. It should be noted that such passive migration is not the same as diffusion. Nevertheless, diffusion of the antifungal agent from the liquid pharmaceutical composition to the nail bed, and particularly to the nail plate, is also specifically contemplated. Thus, a stable, flowable liquid form of terbinafine containing excipients that promote secondary diffusion to the nail plate and create a reservoir of local concentration of the antifungal agent is particularly desirable.
[0071] Moreover, because the compositions provided in this disclosure typically have high antifungal drug concentrations, the liquid pharmaceutical composition acts as a drug delivery system that maintains antifungal drug concentrations (e.g., ≥ 1x the MIC) for at least 30 days after administration, more preferably at least 60 days, and even more preferably at least 90 days.
[0072] It should thus be understood that Terbinafine in a flowable liquid state can be delivered atraumatically and locally under the nail plate and on the surface of the nail bed at very high local concentrations. The delivery of the liquid drug is preferably performed using a small-bore blunt-tip cannula, which avoids damage to the nail bed / nail plate attachment as well as other trauma to the nail anatomy. The concentrated viscous liquid drug is delivered through the cannula and travels to the border of the difficult-to-reach disease site by substantially filling the subungual volume caused by the disease. In this context, it should be noted that the movement of the drug is mainly due to the action of the liquid flow and is less dependent on the diffusion of the drug through the tissue. Drug transport also benefits from the pumping action that results from the periodic pressure pulses that are generated within the nail unit as the patient walks and applies pressure to the toes. It should also be understood that the small-bore cannula is also an effective tool for penetrating the debris created by dermatophytes in the subungual space. Dermatophytosis, a form of fungal disease that produces unsightly yellow ridges on the nails, is caused by a polysaccharide matrix formed by the fungus and is known to be difficult to treat due to poor drug penetration. Cannulation through the diseased matrix and placement of liquid drug to a central location in the affected area has been shown to be a more effective delivery method. Importantly, local delivery of terbinafine to the affected area does not depend on systemic absorption of the drug. The local subungual method of administration can achieve very high local drug concentrations without the hepatotoxicity associated with oral drug administration. EXAMPLES
[0073] Formulation:
[0074] Based on the above considerations, the inventors have prepared various compositions, exemplary formulations of which are shown in Table 1 below. Table 1 JPEG2024167183000002.jpg89166
[0075] Most notably, very high concentrations of terbinafine could be achieved in the hydrophobic carrier. However, only formulations F7 and F8 showed stability under standard conditions (25°C, 60% relative humidity, 9 months storage), whereas formulations F1-F6 eventually precipitated.
[0076] Dosage:
[0077] To determine whether the contemplated formulations could be delivered to the subungual space, the inventors tested access using a 30-gauge blunt cannula (e.g., TSK STERiGLIDE™ Aesthetic Cannula) in several patients with confirmed onychomycosis. Figure 1 depicts an example of a toenail affected by onychomycosis with the borders of the disease marked in black.
[0078] The following protocol was used for all cannulations: Examine the nail unit and perform nail care as necessary (file and sand the dorsal nail plate to ensure optimal visualization of the affected portion of the nail). Measure the width of the nail plate using calipers to identify 2-4 proposed cannulation paths. Measure the length of the affected portion of the nail along each of the proposed cannulation paths and measure the target depth of cannulation for each cannulation path (target insertion depth is 50% of the affected nail length). Cleanse the hyponychium with isopropyl alcohol or povidone-iodine, allow to dry, and record the target depth on a 30-gauge cannula. Insert the cannula along the proposed cannulation path. Use one marked cannula for each proposed cannulation path. Advance the 30-gauge cannula until the tip of the cannula is at the midpoint of the depth of the proposed cannulation path. If cannulation is atraumatic and painless, the cannula may be advanced up to 3 mm further. If possible, mark the location of the nail edge directly above the cannula. Withdraw the cannula and place the retrieved cannula on the surface of the nail plate and photograph. Record the following information for each proposed cannulation route: length of visible onychomycosis; target cannulation depth; actual cannulation depth; ease of cannulation; whether the participant complained of discomfort; and notes on any bleeding observed. After the procedure is completed, wrap the insertion area with a loose dressing or bandage. If any of the second and / or shorter toes have nail involvement greater than 4 mm (2 mm for smaller toes), these nails may be evaluated as well. The cannulation procedure is performed for all cannulations. The study population patients and outcomes are shown in Tables 2 and 3 below. Table 2 JPEG2024167183000003.jpg109166Table 3 JPEG2024167183000004.jpg156166
[0079] As can be readily appreciated, 28 procedures were performed in 12 subjects, all rated by the investigator as "very gentle," all target lengths were reached for all cannulations, there was no bleeding, and there were no spontaneous complaints of pain. Patients perceived 75% of cannulations as pain-free, and the remaining 25% were rated as "very gentle pain" (score 1 on a scale of 1 to 10).
[0080] Tissue concentration:
[0081] To establish a significantly increased amount of terbinafine available in tissues, the inventors compared the tissue concentrations of terbinafine for different modes of administration, specifically, tissue concentrations were determined for oral administration of terbinafine and subungual administration of terbinafine in the form of solid pellets (TMI-358) as described in U.S. Pat. No. 7,135,194, and predicted for subungual administration of terbinafine in a liquid formulation as described in this disclosure.
[0082] Exemplary results for these treatments are shown in Tables 4 and 5. More specifically, Table 4 shows terbinafine concentrations for all treatment options for the nail bed, nail plate, and nail tip, and Table 5 provides a numerical comparison between these methods. Table 4 JPEG2024167183000005.jpg227117Table 5 JPEG2024167183000006.jpg92166
[0083] The results are presented in graphical form in Figure 2. As can be readily seen from Figure 2, when terbinafine was administered orally, the concentration of terbinafine in the nail bed was relatively low. At this time, the terbinafine concentration increased to a steady level due to systemic exposure. In contrast, in the case of subungual delivery using a solid implant, relatively high terbinafine concentrations were achieved, but decreased significantly over time. On the other hand, when terbinafine was administered and firmly retained in the subungual space and treatment space, very high concentrations were achieved and remained significantly higher compared to both alternative administration methods.
[0084] Single agent pharmacokinetics of terbinafine was followed according to topical (4.2 or 42 mg / kg) formulation doses in Hanford minipigs. The test article (HSG) is an antifungal agent (49% terbinafine free base) and a small molecule. Formulation excipients include butylated hydroxytoluene, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate. The concentration of terbinafine free base in HSG is 0.49 mg / μL and the density is 0.98 g / ml.
[0085] Four treatment groups of three Hanford minipigs were divided into groups, including six males and six females. One group of two females and one male received a single dose of 4.2 mg / kg terbinafine applied directly to the skin. One group of two males and one female received a single dose of 4.2 mg / kg terbinafine in the Hill Top chamber. One group of two females and one male received approximately 42 mg / kg terbinafine applied directly to ten sites on the skin. One group of two males and one female received a single dose of 42 mg / kg terbinafine in ten Hill Top chambers.
[0086] As part of a single-dose pharmacokinetic study in Hanford minipigs, one group of 2 females and 1 male received a single dose of 4.2 mg / kg terbinafine applied directly to the skin. One group of 2 males and 1 female received a single dose of 4.2 mg / kg terbinafine in a Hill Top chamber. One group of 2 females and 1 male received a single dose of 42 mg / kg terbinafine applied directly to 10 sites on the skin. One group of 2 males and 1 female received a single dose of 42 mg / kg terbinafine in 10 Hill Top chambers. Blood samples were collected from each animal pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 288 (day 12), 336 (day 14), 384 (day 16), 432 (day 18), and 504 (day 21) hours after dosing to measure plasma terbinafine concentrations for pharmacokinetic analysis. Pharmacokinetic parameters were calculated using WinNonLin software using calculated, rather than nominal, terbinafine doses.
[0087] As part of a single-dose pharmacokinetic study in Hanford minipigs, one group of 2 females and 1 male received a single dose of 4.2 mg / kg terbinafine applied directly to the skin. One group of 2 males and 1 female received a single dose of 4.2 mg / kg terbinafine in a Hill Top chamber. One group of 2 females and 1 male received a single dose of 42 mg / kg terbinafine applied directly to 10 sites on the skin. One group of 2 males and 1 female received a single dose of 42 mg / kg terbinafine in 10 Hill Top chambers. Blood samples were collected from each animal prior to dosing and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 288 (day 12), 336 (day 14), 384 (day 16), 432 (day 18), and 504 (day 21) hours after dosing to measure plasma terbinafine concentrations for pharmacokinetic analysis.
[0088] Dosage and Administration: Place the test sample 4cm above the back 2 The test article was administered once as a topical dose to one area of the skin. The test article was a liquid that was slowly pipetted using the rounded end of a glass rod to rub the material evenly into the area. Group 1 (low dose) was administered to one area and group 2 (high dose) was administered to 10 areas. As the test article (HSG) was running off after dermal administration, it was decided to dose 3 animals / group per protocol and the other 3 animals / group to be dosed using Hill Top chambers (25 mm diameter). The chambers contained 200 μL of test article as a certain amount of test article was needed to wet the Webrill pad inside the chamber.
[0089] Blood Sampling: Pharmacokinetic samples were collected on all study animals. Approximately 4 ml of whole blood was collected at each designated time point via a temporary jugular catheter or by direct venipuncture into the jugular vein or other appropriate vessel. The time allowed for each collection was consistent with SRC SOPs. Blood samples were placed into blood tubes containing K2EDTA as an anticoagulant. Blood / plasma sample tubes were labeled per SRC SOPs. Samples were mixed gently and placed on ice packs or wet ice until processing.
[0090] Samples were centrifuged at 2000xg for approximately 15 minutes at approximately 4° C. Plasma samples were then aliquoted (at least 0.5 mL) into pre-labeled primary and back up cryovials and temporarily frozen on dry ice until storage at approximately −70° C. Samples were shipped chilled on dry ice to a suitable bioanalytical laboratory (KCAS).
[0091] Analytical Methodology: For sample analysis, terbinafine and spiked terbinafine-d7(IS) were extracted from the matrix using liquid / liquid extraction. Following extraction, the residue was then subjected to reversed-phase high performance liquid chromatography on a Pursuit C18 column and analytes were detected by tandem mass spectrometry using a Sciex API5000 LC-MS / MS. The method has been previously validated over the range of 0.0200-2.00ng / ml.
[0092] Pharmacokinetic evaluation: Pharmacokinetic calculations were performed using WinNonlin professional software (Version 4.0.1, Pharsight, Mountain View, CA). Concentration / time data were analyzed using noncompartmental methods (cross-sectional / moment analysis). Peak concentrations (Cmax) and the time of Cmax (Tmax) were obtained directly from the observed data. Plasma terbinafine concentrations below the limit of quantitation of the analytical method (<0.0200) were treated as zero. For this analysis, WinNonlin software selected data points to include in the calculation of λz. WinNonlin software repeated the regression using the last 3, then the last 4, last 5, etc. nonzero concentrations. For each regression, an adjusted R 2 (Adjustment R 2 ) to calculate JPEG2024167183000007.jpg17166
[0093] WinNonlin is the largest adjusted R 2 We estimate λz using the regression with adjusted R 2 does not improve, but the maximum R 2 If the difference was within 0.0001 of the value, a regression with more points was used. The area under the concentration / time curve (AUC) was estimated using a linear trapezoid with linear interpolation.
[0094] Statistical Analysis: No statistical analysis was performed, except for calculations of descriptive statistics. All calculations were performed before rounding of the data. Therefore, when the descriptive statistics and pharmacokinetic parameter values are recalculated using the rounded values in the tables of this report, differences due to rounding may occur.
[0095] Concentration / time profile: Terbinafine plasma concentration / time profiles following single topical administration (single application site) of approximately 4.2 mg / kg terbinafine to two females and one male are shown in Table 6. A graph of terbinafine plasma concentration versus time is shown in Figure 3. Table 6 JPEG2024167183000008.jpg176166
[0096] Terbinafine plasma concentration / time profiles following single topical administration of approximately 4.2 mg / kg terbinafine (single application site) in a hilltop chamber in one female and two males are shown below in Table 7. A graph of terbinafine plasma concentration versus time is shown in Figure 4. Table 7 JPEG2024167183000009.jpg177166
[0097] Terbinafine plasma concentration / time profiles following single topical administration of approximately 42 mg / kg terbinafine (10 application sites) to two females and one male are shown in Table 8. A graph of terbinafine plasma concentration versus time is shown in Figure 5. Table 8 JPEG2024167183000010.jpg170166
[0098] Terbinafine plasma concentration / time profiles following single topical administration of approximately 42 mg / kg terbinafine (10 application sites) in the hilltop chamber in one female and two males are shown in Table 9. A graph of terbinafine plasma concentration versus time is shown in Figure 6. Table 9 JPEG2024167183000011.jpg173166
[0099] A graph of the mean plasma terbinafine concentration versus time for average 4.2 mg / kg and 42 mg / kg terbinafine applied directly to the skin is shown in Figure 7. A graph of the mean plasma terbinafine concentration versus time for average 4.2 mg / kg and 42 mg / kg terbinafine applied in the Hill Top Chamber is shown in Figure 8.
[0100] Pharmacokinetic parameters: The volume of terbinafine applied directly to the skin was 171 μL (83.79 mg) and the amount added to the Hill Top chamber was 200 μL (98.0 mg). The weights of individual animals ranged from 21.4 kg to 30.3 kg. For calculation of pharmacokinetic parameters requiring dose values, the actual dose received by each animal was calculated and is shown in Table 10 below. Any dosing solution that may have been absorbed by the Hill Top chamber pad was not taken into account. The calculated terbinafine dose was used for the pharmacokinetic parameter calculations. Table 10 JPEG2024167183000012.jpg100166
[0101] Estimates of pharmacokinetic parameters following local administration of approximately 4.2 mg / kg terbinafine as a single agent to two females and one male are shown in Table 11 below. Table 11 JPEG2024167183000013.jpg89166
[0102] Estimates of pharmacokinetic parameters following local administration of approximately 4.2 mg / kg terbinafine alone in a hill-top chamber to one female and two males are shown in Table 12 below. Table 12 JPEG2024167183000014.jpg89166
[0103] Estimates of pharmacokinetic parameters following local administration of approximately 42 mg / kg terbinafine as a single agent to two females and one male are shown in Table 13 below. Table 13 JPEG2024167183000015.jpg92166
[0104] Estimates of pharmacokinetic parameters following local administration of approximately 42 mg / kg terbinafine alone in a hill-top chamber to one female and two males are shown in Table 14 below. Table 14 JPEG2024167183000016.jpg89166
[0105] Comparisons of mean pharmacokinetic parameter estimates by dose group, including calculation of high-dose / low-dose parameter ratios, are presented in Table 15 below. Table 15 JPEG2024167183000017.jpg66166
[0106] Topical vs. Oral Administration: A single 250 mg terbinafine tablet (Lamisil®) administered orally to humans results in peak plasma concentrations of approximately 0.97-1.5 μg / mL within 2 hours of administration. The terminal half-life of 200-400 hours is the result of terbinafine being slowly eliminated from tissues such as skin and fat. AUC 48h The absorption rate of topical high-dose terbinafine is slow, with a T max occurred between 24 and 96 hours. Consistent with topical Lamisil, there was minimal penetration of terbinafine into the systemic circulation from topical high-dose terbinafine. max and AUC 0-inf was increased between the 4.2 and 42 mg / kg dose groups applied directly to the skin, but was not dose proportional. The terminal half-life was long, ranging from 196 to 322 hours. For comparison with the same topical dose of high-dose terbinafine (4.2 mg / kg), oral administration of one 250 mg Lamisil® tablet (4.2 mg / kg) results in a peak plasma concentration of 1000 ng / mL within 2 hours after administration. The AUC is approximately 4560 ng·h / mL.
[0107] Notably, single topical administration of the high-concentration formulation at 4.2 mg / kg resulted in mean peak plasma concentrations 227-fold lower (4.4 ng / mL) in three minipigs compared with the same oral dose in humans. Peak plasma concentration AUC from topical administration occurred within 48 to 96 hours after administration. 504h A slow mean terminal half-life of approximately 200 hours was observed, with an AUC of 562 ng hr / mL. Similarly, a larger topical dose of HSG applied to the body surface, 42 mg / kg, 10-fold greater than that of the low-dose group, resulted in mean peak plasma concentrations of 11.1 ng / mL and an AUC 504h The C of the system was 3,077 ng hr / mL. Slow absorption (24-72 hours) and a long mean terminal half-life (322 hours) were demonstrated. A ten-fold increase in surface area and applied dose did not affect the C of the system. max and resulted in a less than proportional increase in AUC.
[0108] As can be seen from the above data, topical / subungual administration advantageously avoids the systemic exposure levels of terbinafine observed during oral delivery, even for high dose formulations. Furthermore, high dose formulations can be administered to the subungual space, which due to its fluid nature distributes substantially throughout the subungual space (while simultaneously being retained within the subungual space). Due to the high concentration, terbinafine can diffuse beyond the subungual space at concentrations above the MIC into a much larger treatment space, including the nail plate and nail bed. Furthermore, due to the high concentration that can be achieved in the nail plate, terbinafine is present above the MIC in the nail plate towards the tip, which itself provides a barrier to fungal growth and ultimately replaces the diseased nail tissue with a healthy nail.
[0109] As used in this disclosure, "administration" of a pharmaceutical composition or agent refers to direct or indirect administration of the pharmaceutical composition or agent. Direct administration is typically performed by a medical professional (e.g., a doctor, a nurse, etc.), while indirect administration includes providing or making available the pharmaceutical composition or agent to a medical professional for direct administration (e.g., injection, infusion, oral delivery, topical delivery, etc.). Furthermore, it is noted that the terms "predicting" or "predicting" a condition, susceptibility to development of a disease, or response to an intended treatment is meant to cover the act of predicting or predicting (but not treating or diagnosing) a condition, susceptibility, and / or response (including progression, amelioration, and / or persistence of a condition in a subject), but not treating or diagnosing.
[0110] All methods described in this disclosure can be performed in any suitable order unless otherwise indicated in this disclosure or clearly contradicted by context. Any and all use of examples or exemplary language (e.g., "etc.") provided with respect to certain embodiments in this disclosure is intended merely to better illustrate the invention and does not limit the scope of the invention, which is otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0111] As used throughout the specification of this disclosure and the appended claims, the meaning of the articles "a," "an," and "the" includes plural references unless the context clearly dictates otherwise. Also, as used in the specification of this disclosure, "in" includes "in" and "on," unless the context clearly dictates otherwise. As used in this disclosure, and unless the context dictates otherwise, the term "coupled to" includes both direct coupling (where two elements are coupled to each other in contact with each other) and indirect coupling (where at least one additional element is present between the two elements). Thus, the terms "coupled to" and "coupled with" are used interchangeably.
[0112] It should be apparent to one skilled in the art that many more modifications besides those already described are possible without departing from the inventive concept in this disclosure. Thus, the subject matter of the invention is not limited except as set forth in the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced element, composition component, or step may be present, utilized, or combined with elements, components, or steps not expressly referenced. When the specification and claims refer to at least one something selected from the group consisting of A, B, C,..., and N, the sentence should be interpreted as requiring only one element from the group, and not requiring A and N, or B and N, etc.
Claims
1. 1. A liquid pharmaceutical composition comprising: a pharma- ceutically acceptable carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, and an optional film-forming agent; and an antifungal agent, A composition, wherein said antifungal agent is dissolved in said pharma- ceutically acceptable carrier and is present in a concentration of 10% by weight or greater, and said pharmaceutical composition has a viscosity of about 500 to 2,500 cP (mPa·s).
2. 2. The composition of claim 1, wherein the hydrophobic solvent is selected from the group consisting of isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and the optional hydrophilic solvent is selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid.
3. The composition of claim 1 or 2, wherein the polymeric film-forming agent comprises a substituted cellulose.
4. The composition of any one of claims 1 to 3, wherein the antifungal agent is an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent.
5. The composition of any one of claims 1 to 4, wherein the antifungal agent is an allylamine antifungal agent.
6. 6. The composition of any one of claims 1 to 5, wherein the antifungal agent is present in a concentration of 20% by weight or greater, and wherein the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity, and wherein the antifungal agent is stable when the composition is stored at 5°C.
7. 7. The composition of any one of claims 1 to 6, wherein the antifungal agent is present in a concentration of 40% by weight or greater, and wherein the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity, and wherein the antifungal agent is stable when the composition is stored at 5°C.
8. The composition according to any one of claims 1 to 7, wherein the composition has a viscosity of about 750 to 1,500 cP (mPa·s).
9. The composition of any one of claims 1 to 8, wherein the hydrophobic solvent comprises isostearic acid, isopropyl myristate, and / or diisopropyl adipate.
10. The composition of any one of claims 1 to 9, wherein the hydrophobic solvent further comprises benzyl alcohol.
11. The composition of any one of claims 1 to 10, wherein the antifungal agent is terbinafine free base.
12. 2. The composition of claim 1, wherein the hydrophobic solvent comprises isostearic acid, diisopropyl adipate, isopropyl myristate, and benzyl alcohol.
13. The composition of claim 12, wherein the polymeric film-forming agent is ethyl cellulose.
14. The composition of claim 13, wherein the antifungal agent is terbinafine free base.
15. 15. The composition of claim 14, wherein the antifungal agent is present in a concentration of 40% by weight or greater.
16. The composition of claim 15, wherein the pharmaceutical composition has a viscosity of about 750 to 1,500 cP (mPa·s).
17. 1. A method of treating a subungual space in a mammal, comprising: administering a liquid pharmaceutical composition to the subungual space between the nail plate and the nail bed; The pharmaceutical composition comprises a pharma- ceutically acceptable carrier comprising a hydrophobic solvent that dissolves, disperses or distributes the therapeutic agent, an optional hydrophilic solvent, and an optional film-forming agent, the pharmaceutical composition having a viscosity of about 500-2,500 cP (mPa·s); The method of claim 1, wherein the therapeutic agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the therapeutic agent in the subungual space and in treatment spaces extending beyond the subungual space.
18. 20. The method of claim 17, wherein the step of administering the liquid pharmaceutical composition comprises inserting a cannula between the nail plate and the nail bed and administering the liquid pharmaceutical composition through the cannula.
19. 20. The method of claim 18, wherein the cannula is a blunt cannula having at least one side hole in a distal portion of the cannula.
20. 20. The method of any one of claims 17 to 19, wherein the subungual space comprises an area infected with a fungus, and the therapeutic agent is an antifungal agent.
21. 20. The method of any one of claims 17-19, wherein the hydrophobic solvent reduces absorption of the therapeutic agent into the systemic circulation and increases absorption of the therapeutic agent into the nail bed compared to dimethylsulfoxide (DMSO) or dimethylformamide (DMF).
22. 22. The method of any one of claims 17 to 21, wherein the step of administering the liquid pharmaceutical composition comprises injecting 10 to 100 μL into the subungual space.
23. 23. The method of any one of claims 17 to 22, wherein administering the liquid pharmaceutical composition further ensures a minimum therapeutic concentration of a therapeutic agent in the nail bed.
24. 24. The method of any one of claims 17 to 23, wherein the polymeric film-forming agent penetrates into the polysaccharide matrix produced by the dermatophyte.
25. The method according to any one of claims 17 to 24, wherein the viscosity of the liquid pharmaceutical composition allows it to flow laterally within the subungual space.
26. 26. The method of any one of claims 17 to 25, wherein the viscosity of said liquid pharmaceutical composition allows retention of 80% or more of an administered amount of said liquid pharmaceutical composition.
27. 27. The method of any one of claims 17 to 26, wherein the hydrophobic solvent is selected from the group consisting of isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and the optional hydrophilic solvent is selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid.
28. The method of any one of claims 17 to 27, wherein the polymeric film-forming agent comprises a substituted cellulose.
29. 29. The method of any one of claims 17 to 28, wherein the therapeutic agent is an antifungal agent selected from the group consisting of an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent.
30. 1. A method for treating onychomycosis comprising: administering subungually a liquid pharmaceutical composition containing a pharma- ceutical acceptable carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, an optional polymeric film-forming agent, and an antifungal agent; the antifungal agent is dissolved in the pharma- ceutical acceptable carrier and is present in a concentration of 10% by weight or more, and the pharmaceutical composition has a viscosity of about 500 to 2,500 cP (mPa·s); The method of claim 1, wherein the antifungal agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the antifungal agent in the subungual space and in treatment spaces extending beyond the subungual space.
31. 31. The method of claim 30, wherein the hydrophobic solvent is selected from the group consisting of isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and the optional hydrophilic solvent is selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid.
32. 32. The method of claim 30 or 31, wherein the polymeric film-forming agent comprises a substituted cellulose.
33. 33. The method of any one of claims 30 to 32, wherein the antifungal agent is an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent.
34. The method of any one of claims 30 to 33, wherein the antifungal agent is an allylamine antifungal agent.
35. 35. The method of any one of claims 30 to 34, wherein the antifungal agent is present in a concentration of 20% by weight or greater and the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity.
36. 36. The method of any one of claims 30 to 35, wherein the antifungal agent is present in a concentration of 40% by weight or greater and the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity.
37. The method of any one of claims 30 to 36, wherein the composition has a viscosity of about 750 to 1,500 cP (mPa·s).
38. 38. The method of any one of claims 30 to 37, wherein the hydrophobic solvent comprises isostearic acid, isopropyl myristate, and / or diisopropyl adipate, and optionally benzyl alcohol.
39. 32. The method of claim 30 or 31, wherein the antifungal agent is terbinafine free base.
40. 1. A method for treating dermatophytosis, comprising: administering the liquid pharmaceutical composition subungually into a polysaccharide matrix located between the nail plate and the nail bed; The liquid pharmaceutical composition comprises a pharma- ceutically acceptable carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, an optional polymeric film-forming agent, and an antifungal agent; the antifungal agent is dissolved in the pharma- ceutical acceptable carrier and is present in a concentration of 20% by weight or more, and the pharmaceutical composition has a viscosity of about 500 to 2,500 cP (mPa·s); The method of claim 1, wherein the antifungal agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the therapeutic agent in the subungual space and in treatment spaces extending beyond the subungual space.
41. 41. The method of claim 40, wherein the hydrophobic solvent is selected from the group consisting of benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and the optional hydrophilic solvent is selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid.
42. 42. The method of claim 40 or 41, wherein the polymeric film-forming agent comprises a substituted cellulose.
43. 43. The method of any one of claims 40 to 42, wherein the antifungal agent is an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent.
44. The method of any one of claims 40 to 43, wherein the antifungal agent is an allylamine antifungal agent.
45. 45. The method of any one of claims 40 to 44, wherein the antifungal agent is present in a concentration of 40% by weight or greater and the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity.
46. The method of any one of claims 40 to 46, wherein the composition has a viscosity of about 750 to 1,500 cP (mPa·s).
47. 47. The method of any one of claims 40 to 46, wherein the hydrophobic solvent comprises isopropyl myristate, and / or diisopropyl adipate, and optionally benzyl alcohol.
48. 48. The method of any one of claims 40 to 47, wherein the antifungal agent is terbinafine free base.
49. 1. A method for retaining a liquid pharmaceutical composition containing an antifungal agent in a subungual space, comprising: administering the liquid pharmaceutical composition subungually to the subungual space; The liquid pharmaceutical composition comprises a pharma- ceutically acceptable carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, an optional polymeric film-forming agent, and the antifungal agent, dissolved in the pharma- ceutically acceptable carrier; The viscosity of the liquid pharmaceutical composition is about 500 to 2,500 cP (mPa s); The method of claim 1, wherein the antifungal agent is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the therapeutic agent in the subungual space and in treatment spaces extending beyond the subungual space.
50. 50. The method of claim 49, wherein 80% or more of the administered volume is retained within the subungual space.
51. 51. The method of claim 49 or 50, wherein 90% or more of the administered volume is retained within the subungual space.
52. 52. The method of any one of claims 49 to 51, wherein the hydrophobic solvent is selected from the group consisting of isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and the optional hydrophilic solvent is selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid.
53. The method of any one of claims 49 to 52, wherein the polymeric film-forming agent comprises a substituted cellulose.
54. 54. The method of any one of claims 49 to 53, wherein the antifungal agent is an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent.
55. The method of any one of claims 49 to 54, wherein the antifungal agent is an allylamine antifungal agent.
56. 56. The method of any one of claims 49 to 55, wherein the antifungal agent is present in a concentration of 20% by weight or greater and the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity.
57. 57. The method of any one of claims 49 to 56, wherein the antifungal agent is present in a concentration of 40% by weight or greater and the composition is stable for at least 4 weeks when stored at 25°C and 60% relative humidity.
58. The method of any one of claims 49 to 57, wherein the composition has a viscosity of about 1,000 to 1,500 cP (mPa·s).
59. 1. A high-dose antifungal liquid pharmaceutical composition comprising: a pharma- ceutically acceptable carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, an optional polymeric film-forming agent, and an antifungal agent, at a concentration of 30% or more by weight of the composition; the antifungal agent is dissolved in the pharma- ceutically acceptable carrier, and the composition is stable for at least 4 weeks when stored at 25° C. and 60% relative humidity; A composition, wherein the concentration of the pharmaceutical composition is about 500 to 2,500 cP (mPa·s).
60. 60. The high-dose antifungal composition of claim 59, wherein the antifungal agent is present in a concentration of 40% or more by weight of the composition.
61. 61. The high-dose antifungal composition of claim 59 or 60, wherein the antifungal agent is stable for at least 3 months when the composition is stored at 25°C and 60% relative humidity.
62. The high-dose antifungal composition of any one of claims 59 to 61, wherein the antifungal agent is stable for at least 6 months when the composition is stored at 25°C and 60% relative humidity.
62. 62. The high-dose antifungal composition of any one of claims 59 to 61, wherein the hydrophobic solvent is selected from the group consisting of isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate, and the optional hydrophilic solvent is selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid.
63. 63. The high-dose antifungal composition of any one of claims 59 to 62, wherein the polymeric film-forming agent comprises a substituted cellulose.
64. 64. The high-dose antifungal composition of any one of claims 59 to 63, wherein the antifungal agent is an allylamine antifungal agent, a morpholine antifungal agent, a polyene antifungal agent, or an azole antifungal agent.
65. 65. The high-dose antifungal composition of any one of claims 59 to 64, wherein the antifungal agent is terbinafine free base.
66. The high-dose antifungal composition according to any one of claims 59 to 65, wherein the pharmaceutical composition has a viscosity of about 750 to 1,500 cP (mPa·s).
67. 1. A method for treating onychomycosis comprising: administering the liquid pharmaceutical composition subungually at a location that does not contact the visible proximal end of an onychomycosis lesion, wherein the composition comprises a pharma- ceutically acceptable carrier comprising a hydrophobic solvent, an optional hydrophilic solvent, an optional polymeric film-forming agent, and an antifungal agent dissolved in the hydrophobic solvent, and the viscosity of the pharmaceutical composition is about 500 to 2,500 cP (mPa·s); transferring the liquid pharmaceutical composition from said location to at least said visible proximal end of said affected area of onychomycosis. wherein the onychomycosis is present in the pharmaceutical composition in an amount that ensures a minimum inhibitory concentration of the therapeutic agent in the subungual space and in a treatment space extending beyond the subungual space.
68. 68. The method of claim 67, wherein the location is more than 1 mm away from the visible proximal edge of the affected area of onychomycosis.
69. 68. The method of claim 67, wherein the location is more than 3 mm away from the visible proximal edge of the affected area of onychomycosis.
70. 70. The method of any one of claims 67-69, wherein said subungual administration comprises delivering said liquid pharmaceutical composition through a blunt cannula.
71. A liquid antifungal composition comprising: a pharma- ceutically acceptable carrier comprising a hydrophobic solvent selected from the group consisting of isostearic acid, benzyl alcohol, diisopropyl adipate, diethyl sebacate, and isopropyl myristate; any hydrophilic solvent selected from the group consisting of dimethyl isosorbide, propylene carbonate, and D,L-lactic acid; substituted cellulose as an optional polymeric film-forming agent; and terbinafine, wherein the concentration of the terbinafine is 20% by weight or more; The liquid antifungal composition has a viscosity of about 500 to 2,500 cP (mPa·s).
72. 72. The antifungal composition of claim 71, wherein the concentration of terbinafine is 30% by weight or more.
73. The antifungal composition of claim 71, wherein the concentration of terbinafine is 40% by weight or more.
74. 72. The antifungal composition of claim 71, wherein the terbinafine is terbinafine free base.
75. The antifungal composition according to any one of claims 71 to 74, wherein the pharmaceutical composition has a viscosity of about 750 to 1,500 cP (mPa·s).
76. 75. The antifungal composition of any one of claims 71 to 74, wherein the pharma- ceutically acceptable carrier comprises isostearic acid, diisopropyl adipate, or isopropyl myristate.
77. The antifungal composition according to any one of claims 71 to 74, wherein the polymeric film-forming agent is ethyl cellulose.
78. 77. The antifungal composition of claim 76, wherein the polymeric film-forming agent is ethyl cellulose.
79. Use of the liquid antifungal composition according to any one of claims 71 to 78 in the treatment of onychomycosis and / or dermatophytosis.
80. 80. The use of claim 79, wherein the treatment comprises non-traumatic delivery of the liquid antifungal composition to the subungual space.
Citation Information
Patent Citations
External antifungal preparation for nail
JP2004083439A
Subungual antifungal medications and methods for treating onychomycosis (nail fungus).
JP2010504345A
Antifungal drug composition
JP2013528157A
External preparation for nail
WO2006013963A1
